Merck acquisition brings back hope for Harpoon’s trispecific technology

With Merck’s acquisition of trispecific antibody-based therapy company Harpoon, optimism is building around the DLL3 target and its potential to treat some of the most challenging cancer indications. 

Merck & Co. Inc. (NYSE:MRK) will acquire Harpoon Therapeutics Inc. (NASDAQ:HARP) for $23 per share, for a total equity value of about $680 million. The price represents a 118% premium over Friday’s close of $10.55, but well below the company’s 2019 IPO price after a 10:1 reverse stock split in September. ...